Funding will accelerate development of first-in-class small-molecule drugs for a condition with no approved targeted ...

BOULDER — Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round. Think Bioscience Inc. recently raised an oversubscribed $55 million Series A round.

The littlest wolf in the pack was the star of the show Wednesday, Jan. 14 at the Paws Out, Claws Out fundraiser during ...

To the best of our knowledge, there have been no previously published reports in the medical literature of phytobezoars in patients with Noonan syndrome. This case represents what may be an ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more effective ...

Noonan syndrome (NS) and Noonan syndrome with multiple lentigines (NS-ML) are rare human developmental disorders caused by mutations of the protein SHP2. Until recently, the mechanism of NS and NS-ML ...

Vosoritide's first global Phase II study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to ...

Vosoritide's first global Phase II study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to ...